← Leaderboards
Tarik Soliman
Extend Biosciences, Inc.
$3,385,711
Attributed
$3,385,711
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.4M · FY2013–19$2M$1.5M$1M$500K$0
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$3,385,711 · 4
By mechanism
R44$2,212,084 · 1
R43$1,173,627 · 3
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Drug Kinetics”
- Leonard Freedman · Leidos Biomedical Research, Inc.$241,865,009
- Sharon A Nachman · Johns Hopkins University$194,646,762
- Carol Nesel · Westat$147,274,423
- Barbara Driver · Westat, Inc.$103,746,400
- Ronald T Mitsuyasu · University Of California Los Angeles$99,239,507
- Lynn Briscoe · Leidos Biomedical Research, Inc.$93,714,869
Research focus
Drug KineticsPharmacodynamicsBiological SciencesBasePharmaceutical PreparationsAnimal ModelSmall Business Innovation Research GrantDoseHalf-LifeAnimalsLeadPeptidesPropertyAmino AcidsQuality Of LifeHormonesEfficacy TestingInflammatoryChemotherapyGhrelinBiological MarkersHome EnvironmentClinicIntravenous Infusion Procedures
Grant awards (6)
Long-acting ghrelin for neuropathy$535,325
R43 · FY2019 · NS · contact PI
Long-acting ghrelin for the treatment of cancer cachexia$2,084
R44 · FY2019 · CA · contact PI
Long-acting ghrelin for the treatment of cancer cachexia$1,377,076
R44 · FY2018 · CA · contact PI
Long-acting ghrelin for the treatment of cancer cachexia$832,924
R44 · FY2017 · CA · contact PI
Ultralong-acting insulin for diabetes$350,000
R43 · FY2017 · DK · contact PI
Long lasting ghrelin derivatives for the treatment of cancer cachexia$288,302
R43 · FY2013 · CA · contact PI